Product
CAR.CD30 T cells
1 clinical trial
2 indications
Indication
Non-Hodgkin lymphomaIndication
Hodgkin lymphomaClinical trial
Phase I Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor for Relapsed CD30+ Hodgkin's Lymphoma and CD30+ Non-Hodgkin's Lymphoma (CART CD30)Status: Withdrawn, Estimated PCD: 2016-01-28